Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Douglas, Dieterich"'
Autor:
Sonal Kumar, Arpan Mohanty, Parvez Mantry, Robert E. Schwartz, Madeleine Haff, George Therapondos, Mazen Noureddin, Douglas Dieterich, Nigel Girgrah, Kristi Cohn, Mohanish Savanth, Michael Fuchs
Publikováno v:
BMC Primary Care, Vol 25, Iss 1, Pp 1-10 (2024)
Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease, impacts 30% of the global population. This educational pilot focused on the role primary care providers ma
Externí odkaz:
https://doaj.org/article/13d7026a37a945ca839be69c47a57159
Autor:
Douglas Dieterich, Camilla Graham, Su Wang, Paul Kwo, Young-Suk Lim, Chun-Jen Liu, Kosh Agarwal, Mark Sulkowski
Publikováno v:
Gastro Hep Advances, Vol 2, Iss 2, Pp 209-218 (2023)
Background and Aims: Hepatitis B virus (HBV) infection continues to threaten millions of lives across the globe, despite universal vaccination efforts. Current guidelines for screening, vaccination, and treatment are complex and have left too many pe
Externí odkaz:
https://doaj.org/article/a2f14aa525b9441b8dc4187c5008030e
Autor:
Calvin Q. Pan, Nezam H. Afdhal, Victor Ankoma‐Sey, Ho Bae, Michael P. Curry, Douglas Dieterich, Lynn Frazier, Andrew Frick, Hie‐Won Hann, W. Ray Kim, Paul Kwo, Scott Milligan, Myron J. Tong, K. Rajender Reddy
Publikováno v:
Hepatology Communications, Vol 6, Iss 8, Pp 1881-1894 (2022)
Abstract Real‐world data are limited on tenofovir alafenamide (TAF). We aimed to study TAF real‐world outcomes with other first‐line regimens for chronic hepatitis B (CHB). We enrolled patients with CHB from 10 centers retrospectively and follo
Externí odkaz:
https://doaj.org/article/c069a6f091ce4455a5cb4d4d17687cc2
Autor:
Ning Ma, Rowena Yip, Sara Lewis, Amreen Dinani, Christina Wyatt, Michael Crane, Artit Jirapatnakul, Li Li, Costica Aloman, Meena B. Bansal, Douglas Dieterich, Brooke Wyatt, David Yankelevitz, Claudia Henschke, Andrea D. Branch
Publikováno v:
JHEP Reports, Vol 5, Iss 4, Pp 100696- (2023)
Background & Aims: The prevalence and aetiology of liver fibrosis vary over time and impact racial/ethnic groups unevenly. This study measured time trends and identified factors associated with advanced liver fibrosis in the United States. Methods: S
Externí odkaz:
https://doaj.org/article/62dbf390394a4395923a5820fb86f3e5
Autor:
Young-Suk Lim, W. Ray Kim, Douglas Dieterich, Jia-Horng Kao, John F. Flaherty, Leland J. Yee, Lewis R. Roberts, Homie Razavi, Patrick T. F. Kennedy
Publikováno v:
Viruses, Vol 15, Iss 4, p 997 (2023)
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current internatio
Externí odkaz:
https://doaj.org/article/b0f820d04b534e6eae9f1231aec2919b
Autor:
Tatyana Kushner, MD, MSCE, Ben L. Da, MD, Aryana Chan, AGNP, Douglas Dieterich, MD, Keith Sigel, MD, PhD, Behnam Saberi, MD
Publikováno v:
Transplantation Direct, Vol 8, Iss 1, p e1253 (2022)
Background. Without available curative therapies for delta hepatitis (hepatitis delta virus [HDV]), hepatic decompensation and hepatocellular carcinoma (HCC) among HDV patients often necessitates liver transplantation (LT). The objective of this stud
Externí odkaz:
https://doaj.org/article/9be36a7bd2fe43da954f28e622a89f12
Publikováno v:
Clinics in Liver Disease. 26:229-243
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder that leads to chronic kidney disease and end-stage kidney disease (ESKD). Polycystic liver disease (PCLD) is the most common extrarenal manifestation of ADPKD. Though isolated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc5167a3a87e7a6b386d102f0916da72
https://doi.org/10.1016/j.cld.2022.01.009
https://doi.org/10.1016/j.cld.2022.01.009
Autor:
Donald M. Jensen, Tarik Asselah, Douglas Dieterich, Graham R. Foster, Mark S. Sulkowski, Stefan Zeuzem, Parvez Mantry, Eric M. Yoshida, Christophe Moreno, Denis Ouzan, Mark Wright, Luis E. Morano, Robert Buynak, Marc Bourlière, Tarek Hassanein, Shuhei Nishiguchi, Jia-Horng Kao, Masao Omata, Seung W. Paik, David K. Wong, Edward Tam, Kelly Kaita, S. Victor Feinman, Jerry O. Stern, Joseph Scherer, Anne-Marie Quinson, Florian Voss, John-Paul Gallivan, Wulf O. Böcher, Peter Ferenci
Publikováno v:
Annals of Hepatology, Vol 15, Iss 3, Pp 333-349 (2016)
Introduction & aim. Faldaprevir is a potent once-daily (q.d.) hepatitis C virus (HCV) NS3/4A protease inhibitor. The STARTVerso1 and STARTVerso2 phase 3 studies evaluated faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naï
Externí odkaz:
https://doaj.org/article/dda945401c9c4406bf45486119425e6e
Autor:
Barbra Cave, Marina Serper, Terry Box, Christian Ramers, Tuesdae Stainbrook, Nancy Reau, Stacey Trooskin, Mark Sulkowski, Douglas Dieterich, Amreen Dinani
Publikováno v:
Gastroenterology & Hepatology: Open Access. 13:12-20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f66a82b8c80e57d0d504bd2e87ef9d2
https://doi.org/10.15406/ghoa.2022.13.00488
https://doi.org/10.15406/ghoa.2022.13.00488
Autor:
Shai S. Shemesh, James Douglas Dieterich, Darwin Chen, Roni Sharon, Michael J. Bronson, Tal Frenkel Rutenberg, Calin S. Moucha
Publikováno v:
Journal of Personalized Medicine
Volume 13
Issue 2
Pages: 216
Volume 13
Issue 2
Pages: 216
Background: Both pain catastrophizing and neuropathic pain have been suggested as prospective risk factors for poor postoperative pain outcomes in total joint arthroplasty (TJA). Objective: We hypothesized that pain catastrophizers, as well as patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a057d531b7021c76f92c43d1884b1fa0